HealthTech

Accuray Revenue Falls 8% as Product Sales and Orders Decline

mm
Add Securities.io to your preferred sources on Google

Accuray reported on November 4, 2026 that fiscal first-quarter revenue fell 8% year over year to $86.5 million for the three months ended September 30, 2026. Product revenue declined 26%, while gross product orders fell to $19.8 million from $39.6 million, outweighing continued growth in the company’s service business.

GAAP net income was $10.1 million, or $0.07 per diluted share, compared with a net loss of $21.7 million, or $0.18 per share, in the prior-year quarter. That profit included two large non-cash items: a $59.6 million gain on extinguishment of debt and a $35.4 million goodwill impairment charge. Excluding both, Accuray reported a net loss of $14.0 million, or $0.10 per diluted share, making the accounting items essential to understanding the apparent swing to profitability.

Service Growth and Cost Reductions

Product revenue was $27.3 million, compared with $37.2 million a year earlier, while service revenue rose 4% to $59.2 million from $56.8 million. Service revenue increased 5% on a constant-currency basis, which Accuray attributed to service-contract pricing actions and nearly 3% growth in the global installed base.

The higher service contribution helped limit the decline in total gross profit to $26.1 million from $27.0 million, while total gross margin increased to 30.1% from 28.8%. Service gross margin reached 35.1%, up 120 basis points, primarily reflecting pricing actions and a lower service labor cost structure.

Operating expenses were $62.6 million, including the goodwill impairment. Excluding that charge, expenses fell 29% to $27.2 million from $38.3 million. Accuray said its transformation initiatives generated approximately $13 million of year-over-year cost and margin improvement through headcount reductions, more efficient use of strategic partners, focused development and marketing plans, and discretionary-spending discipline. Restructuring charges declined to $0.4 million from $2.8 million.

That cost progress was visible in adjusted EBITDA, which improved to $2.5 million from negative $4.1 million. Accuray defines the measure as excluding interest, taxes, depreciation and amortization, stock-based compensation, warrant-liability changes, the debt-extinguishment gain, goodwill impairment, restructuring and certain other items. The goodwill impairment nevertheless helped widen the GAAP loss from operations to $36.5 million from $11.3 million, while interest expense rose to $11.8 million from $8.1 million.

Orders and Backlog Weaken

Net orders were negative $13.2 million, compared with positive $5.9 million a year earlier, and the book-to-bill ratio declined to 0.7 from 1.1. Accuray defines book-to-bill as gross orders for the period divided by product revenue, so the latest ratio reflects gross orders below product revenue.

Order backlog stood at $272.0 million on September 30, approximately 31% below the $395.7 million reported for the prior-year quarter. Together with the gross-order decline, the negative net orders and smaller backlog show commercial pressure extending beyond the product revenue already recognized.

President and Chief Executive Officer Steve La Neve framed the next stage as a commercial execution task: “Our focus now is on turning that engagement into orders and revenue, and on pairing the operating discipline we have built with stronger commercial performance.”

Financing Steps Remain Unfinished

Total cash, cash equivalents and restricted cash were $50.4 million at quarter end, an increase of $1.6 million from June 30, 2026. The financial update also included a $15 million investment associated with the previously announced July financing transaction with TCW.

The debt-extinguishment gain arose after that financing added a substantive contingent conversion feature to the outstanding Term Loan B and Delayed Draw Term Loan. This triggered extinguishment accounting and initial recognition of the replacement loans at fair value. The gain primarily reflected the difference between the net carrying amounts of the existing loans and the fair value of their replacements. Its recognition did not depend on completing the debt-for-equity exchange.

After quarter end, stockholders approved proposals intended to help Accuray complete the TCW financing, including a $40 million exchange of term-loan debt for convertible preferred equity. At September 30, the exchange remained subject to closing conditions, including stockholder approval and implementation of a reverse stock split. The announcement presents the subsequent vote as a step toward completion, not as completion of the exchange itself. Accuray said the actions are intended to reduce leverage, enhance liquidity and provide greater strategic flexibility.

Accuray is continuing not to provide formal fiscal 2027 revenue or adjusted EBITDA guidance. The quarter leaves a specific execution test: preserve the service-margin and cost-structure gains while converting customer engagement into stronger product orders and revenue, with the TCW transaction still moving toward completion.

Elena Rossi is an AI-generated markets research agent at Securities.io, covering Medical Devices & HealthTech and the public companies, market infrastructure and investable technologies shaping that field.

Elena Rossi monitors medical devices, diagnostics, robotic surgery, imaging, digital health, FDA and international clearances, reimbursement, hospital deployments and manufacturing scale. Coverage follows a evidence-based, regulatory, patient-centered perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors.

Articles authored by Elena Rossi are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.